Nurix Therapeutics Inc
NRIX11.070USD
+0.030+0.27%
交易中 （美東）報價延遲15分鐘
846.12M總市值
虧損本益比TTM
關於 Nurix Therapeutics Inc 公司
Nurix Therapeutics, Inc. 是一家臨牀階段生物製藥公司。該公司專注於發現、開發和商業化靶向蛋白質降解藥物，旨在改善癌症和炎症疾病患者的治療選擇。其全資擁有的臨牀階段產品線包括三種在研候選藥物：NX-5948，一種高選擇性布魯頓酪氨酸激酶 (BTK) 降解劑；NX-2127，一種 BTK 和轉錄因子 IKZF1 (Ikaros) 和 IKZF3 (Aiolos) 的雙重降解劑；NX-1607，一種 Casitas B 系淋巴瘤原癌基因 B (CBL-B) 抑制劑，CBL-B 是一種 E3 連接酶，可調節多種免疫細胞類型（包括 T 細胞和 NK 細胞）的激活。該公司還在其臨牀前產品線中推進多種降解劑和降解抗體偶聯物 (DAC)。其合作藥物研發管線包括 IRAK4 和 STAT6 的臨牀前階段降解劑以及多個附加項目。
公司簡介
公司代碼NRIX
公司名稱Nurix Therapeutics Inc
上市日期Jul 24, 2020
CEODr. Arthur T. Sands, M.D., Ph.D.
員工數量286
證券類型Ordinary Share
年結日Jul 24
公司地址1700 Owens St Ste 205
城市SAN FRANCISCO
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編94158
電話14156605320
網址https://www.nurixtx.com/
公司代碼NRIX
上市日期Jul 24, 2020
CEODr. Arthur T. Sands, M.D., Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Arthur T. Sands, M.D., Ph.D.
Dr. Arthur T. Sands, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
908.33K
--
Dr. Christine Ring, J.D., Ph.D.
Dr. Christine Ring, J.D., Ph.D.
Chief Legal Officer, Chief Compliance Officer, Secretary
Chief Legal Officer, Chief Compliance Officer, Secretary
44.01K
+17.93%
Dr. David L. Lacey, M.D.
Dr. David L. Lacey, M.D.
Independent Director
Independent Director
33.33K
--
Mr. Hans van Houte
Mr. Hans van Houte
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Wolffe, Ph.D.
Ms. Elizabeth Wolffe, Ph.D.
Investor Relations
Investor Relations
--
--
Mr. Paul M. Silva
Mr. Paul M. Silva
Independent Director
Independent Director
--
--
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Edward C. (Ed) Saltzman
Mr. Edward C. (Ed) Saltzman
Independent Director
Independent Director
--
--
Dr. Roy D. Baynes, M.D., Ph.D.
Dr. Roy D. Baynes, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Lori A. Kunkel, M.D.
Dr. Lori A. Kunkel, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Arthur T. Sands, M.D., Ph.D.
Dr. Arthur T. Sands, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
908.33K
--
Dr. Christine Ring, J.D., Ph.D.
Dr. Christine Ring, J.D., Ph.D.
Chief Legal Officer, Chief Compliance Officer, Secretary
Chief Legal Officer, Chief Compliance Officer, Secretary
44.01K
+17.93%
Dr. David L. Lacey, M.D.
Dr. David L. Lacey, M.D.
Independent Director
Independent Director
33.33K
--
Mr. Hans van Houte
Mr. Hans van Houte
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Wolffe, Ph.D.
Ms. Elizabeth Wolffe, Ph.D.
Investor Relations
Investor Relations
--
--
Mr. Paul M. Silva
Mr. Paul M. Silva
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月1日 週五
更新時間: 8月1日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
12.02%
BlackRock Institutional Trust Company, N.A.
7.81%
Deep Track Capital LP
7.19%
The Vanguard Group, Inc.
5.76%
Redmile Group, LLC
5.30%
Other
61.91%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
12.02%
BlackRock Institutional Trust Company, N.A.
7.81%
Deep Track Capital LP
7.19%
The Vanguard Group, Inc.
5.76%
Redmile Group, LLC
5.30%
Other
61.91%
股東類型
持股股東
佔比
Investment Advisor
44.05%
Hedge Fund
30.81%
Investment Advisor/Hedge Fund
29.53%
Research Firm
3.16%
Venture Capital
1.77%
Individual Investor
1.41%
Private Equity
0.97%
Pension Fund
0.47%
Sovereign Wealth Fund
0.42%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
377
87.00M
113.82%
-2.77M
2025Q1
389
86.54M
113.52%
-3.63M
2024Q4
375
82.62M
109.55%
+7.81M
2024Q3
364
70.42M
104.89%
-2.21M
2024Q2
348
68.70M
107.62%
+7.14M
2024Q1
317
52.13M
105.94%
-5.88M
2023Q4
312
49.16M
101.34%
-6.38M
2023Q3
304
48.27M
100.23%
-5.64M
2023Q2
307
47.72M
99.11%
-5.99M
2023Q1
304
45.84M
96.69%
-8.16M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
9.19M
12.06%
-370.83K
-3.88%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.97M
7.83%
+323.12K
+5.72%
Mar 31, 2025
Deep Track Capital LP
5.50M
7.21%
+1.38M
+33.33%
Mar 31, 2025
The Vanguard Group, Inc.
4.40M
5.77%
+69.86K
+1.61%
Mar 31, 2025
Redmile Group, LLC
4.05M
5.32%
-140.70K
-3.36%
Mar 31, 2025
Commodore Capital LP
3.98M
5.22%
+128.91K
+3.35%
Mar 31, 2025
Baker Bros. Advisors LP
3.88M
5.09%
--
--
Mar 31, 2025
Wellington Management Company, LLP
3.19M
4.18%
-397.86K
-11.09%
Mar 31, 2025
State Street Global Advisors (US)
2.86M
3.75%
+57.96K
+2.07%
Mar 31, 2025
T. Rowe Price Associates, Inc.
2.82M
3.7%
-99.19K
-3.40%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ARK Genomic Revolution ETF
1.72%
Tema Oncology ETF
1.25%
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
SPDR S&P Biotech ETF
0.22%
iShares Micro-Cap ETF
0.19%
Direxion Daily S&P Biotech Bull 3X Shares
0.12%
Invesco Nasdaq Biotechnology ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.1%
iShares Biotechnology ETF
0.09%
Fidelity Fundamental Small-Mid Cap ETF
0.08%
查看更多
ARK Genomic Revolution ETF
佔比1.72%
Tema Oncology ETF
佔比1.25%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.86%
SPDR S&P Biotech ETF
佔比0.22%
iShares Micro-Cap ETF
佔比0.19%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.12%
Invesco Nasdaq Biotechnology ETF
佔比0.1%
ProShares Ultra Nasdaq Biotechnology
佔比0.1%
iShares Biotechnology ETF
佔比0.09%
Fidelity Fundamental Small-Mid Cap ETF
佔比0.08%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
